36C26025Q0926_1 FOR SAM.docx

36C26025Q0926

PAGE 1 OF

1. REQUISITION NO.

2. CONTRACT NO.

3. AWARD/EFFECTIVE DATE

4. ORDER NO.

5. SOLICITATION NUMBER

6. SOLICITATION ISSUE DATE

a. NAME

b. TELEPHONE NO. (No Collect Calls)

8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY

CODE

10. THIS ACQUISITION IS

UNRESTRICTED OR

SET ASIDE:

% FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ

IFB

RFP

15. DELIVER TO

CODE

16. ADMINISTERED BY

CODE

17a. CONTRACTOR/OFFEROR

CODE

FACILITY CODE

18a. PAYMENT WILL BE MADE BY

CODE

TELEPHONE NO.

UEI:

EFT:

PHONE:

FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19.

20.

21.

22.

23.

24.

ITEM NO.

SCHEDULE OF SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA

26. TOTAL AWARD AMOUNT (For Govt. Use Only) 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________

29. AWARD OF CONTRACT: REF. ___________________________________ OFFER

COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND

DATED ________________________________. YOUR OFFER ON SOLICITATION

DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY

(BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE

ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED

SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) 30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

(REV. NOV 2021)

PREVIOUS EDITION IS NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

10-29-2025 Eric Lingenfelter 360-852-9891 11-12-2025 17:00

PDT

36C260 Network Contracting Office 20

ATTN: V4CONT

1601 E. Fourth Plain Blvd Bldg.17, Suite B428 Vancouver WA 98661

X

325413 1250 Employees

NET 30 DAYS

N/A

36C648 Department of Veterans Affairs Portland Health Care System 3710 NW US Veterans Hospital Road

Portland OR 97239-2999 36C260 Network Contracting Office 20

ATTN: V4CONT

1601 E. Fourth Plain Blvd Bldg.17, Suite B428 Vancouver WA 98661

Dept of Veterans Affairs

FMS-VA-2(101)

Financial Services Center

PO BOX 149971

Austin TX 78714-9971

a. Location: VA Portland Health Care System

b. Supplies Being Requested: Cost Per Reportable Result, Automated Chemistry Immunochemistry Instrumentation.

c. This will be awarded as a Five-Year Indefinite Delivery Indefinite Quantity (IDIQ) Contract, with a minimum guarantee of $5,000.00, and a total capacity of $7,499,999.99.

d. Period of Performance: 12/01/2025 - 11/30/2030.

e. B.3 PRICE/COST SCHEDULE Contains Additional Information.

f. VA POC for this Solicitation, Eric Lingenfelter, eric.lingenfelter@va.gov, 360-852-9891.

One(1)

Jose Ronstadt Contracting Officer

Table of Contents

SECTION B - CONTINUATION OF SF 1449 BLOCKS

B.1 CONTRACT ADMINISTRATION DATA

1. Contract Administration: All contract administration matters will be handled by the following individuals:

a. CONTRACTOR:

b. GOVERNMENT: Contracting Officer 36C260 Network Contracting Office 20

ATTN: V4CONT

1601 E. Fourth Plain Blvd Bldg.17, Suite B428 Vancouver WA 98661

2. CONTRACTOR REMITTANCE ADDRESS: All payments by the Government to the contractor will be made in accordance with:

3. INVOICES: Invoices shall be submitted in arrears:

4. GOVERNMENT INVOICE ADDRESS: All Invoices from the contractor shall be submitted electronically in accordance with VAAR Clause 852.232-72 Electronic Submission of Payment Requests.

https://www.tungsten-network.com/customer-campaigns/veteransaffairs/

ACKNOWLEDGMENT OF AMENDMENTS: The offeror acknowledges receipt of amendments to the Solicitation numbered and dated as follows:

Page 1 of

B.2 STATEMENT OF WORK

IDIQ LANGUAGE

1.1. INTENT: it is the intent of the Department of Veterans Affairs, (herein afterwards referred to as VHAPORHCS to establish a Indefinite Delivery – Indefinite Quantity (IDIQ) for Automated Chemistry Immunochemistry Instrumentation or continuation of current Automated Chemistry Immunochemistry Instrumentation. a CPRR. Contractor agrees to the following terms of the IDIQ exclusively with VAPORHCS awarded in the final IDIQ. Additional tests/reagents/instrumentation may be added to the IDIQ as new technology becomes available on the market and added to the IDIQ.

1.2. ORDERS: All products ordered under this IDIQ are subject to the terms and conditions of the contract. This IDIQ does not obligate any funds. The Government is obligated only to the extent of authorized orders actually issued under the IDIQ by authorized individuals.

1.3. PRICES AND TERMS: VAPORHCS will provide an estimated annual volume by test as reflected in Attachment A. The Government estimates the volumes at VAPORHCS as listed in Attachment A, but does not guarantee volumes as listed; they are estimates ONLY. The facility will fax, email or upload their test counts from the chemistry analyzers. By the 10th of the following month to the contractor.

1.4. TERM OF AGREEMENT: This will be a firm-fixed price IDIQ with five one-year ordering periods. and shall be effective for the term of the IDIQ. This IDIQ shall be reviewed annually. VAPORHCS intends to establish the first ordering period of the agreement for the period of 12/1/2025 through 11/30/2026.

1.5. IDENTIFICATION: Delivery Orders issued shall be identified by their applicable IDIQ Number and Internal Order Number. Delivery identification numbers are assigned through the VHA Procurement Activity;

1.6. ORDERING METHOD: The participating facilities may order products via Electronic Data Interchange (EDI), telephone, facsimile or other written communication, identifying the products by number, quantity, purchase price, address for delivery, and any special instructions.

DESCRIPTION/SPECIFICATIONS/TECHNICAL EVALUATION PLAN

SCOPE OF PROCUREMENT:

1.6.1. The desired instrumentation shall have the capability of performing or reporting the clinical parameters as defined in the Technical Evaluation Plan. The instrument shall have random access capability (if discrete testing is required) and be able to simultaneously perform the complete profile as described below meeting the performance characteristics for accuracy and precision as defined by the 1988 Clinical Laboratory Improvement Act (CLIA) and the Clinical and Laboratory Standards Institute (CLSI).

1.6.2. If Contractor offers an integrated family of analyzers, the technical evaluation panel will determine if instrumentation proposed meets needs of using facility.

1.6.3. Equipment shall be acquired for the clinical laboratory located at the VAPORHCS.

1.6.4. The Contractor is required to provide a continuously stocked inventory of reagents, standards, Vendor provided Controls, supplies, disposables and any other materials, to include replacement parts, required to properly perform tests on the equipment such that equipment operations are not interrupted. These items shall be of the highest quality, sensitivity, specificity and tested to assure precision and accuracy. Expiration date must be clearly marked on reagent, standards and control containers. Unexpected changes in methodology/technology shall be at the expense of the Contractor. Alert/Notification of any delays in shipment as well as any or all technical advisory/recalls/alerts, prior to or simultaneously with field alerts should be forwarded to the designated individuals determined at contract award.

1.6.5. Contractor is required to provide vendor controls for troubleshooting and/or routine use as needed.

1.6.6. The Contractor shall provide a detailed list of all parts, supplies and their costs that are to be purchased by the facility and are not included in the CPRR contract.

1.6.7. Special handling for emergency orders of supplies: In the event that the supplies are found to be defective and unsuitable for use with the Contractor’s equipment, or the Contractor has failed to comply with the requirements for routine supply delivery, the Contractor is required to deliver the supplies within 24 hours of receipt of a verbal order for emergency delivery. If either circumstance has occurred, the Contractor shall deliver to the Government site in the most expeditious manner possible without a`dditional cost to the Government, the necessary consumables in sufficient quantity as required to allow operation of the Contractor’s equipment for one week (under normal Government test load volume). If additional requests for emergency supply delivery are required by the Government, they shall be honored by the Contractor until the arrival at the laboratory of the monthly standing order/routine supplies delivery.

1.7. DEFINITIONS:

1.7.1. Cost per Patient Reportable Result (CPRR)- Contractors are required to provide a price for a reportable patient result. The per patient reportable result price shall include costs covering: (1) 5 year equipment use, (2) all reagents, standards, Vendor provided quality Controls, supplies, consumable/disposable items, parts, accessories and any other item required for the proper operation of the Contractor’s equipment and necessary for the generation of a patient reportable result. This per patient reportable result price shall also encompass all costs associated with dilution; repeat and confirmatory testing required to produce a single patient reportable result. It shall also include the material to perform as well as all other costs associated with quality control, calibration and correlation study testing that is prescribed by the Clinical and Laboratory Standards Institute (CLSI). (3) all necessary maintenance to keep the equipment in good operating condition (This element includes both preventive maintenance and emergency repairs) and (4) training for Government personnel. Contractors shall provide delivery, installation and removal of equipment at no additional charge. (5) All necessary items covered and not covered under the cost per reportable that are required to maintain and operate instrument shall be listed in bid as well. This includes such things as sample probes, lamps, and other supplies. An estimated usage/cost per year shall be included as well.

1.7.2. Cost per Test (CPT)- as defined in the Federal Supply Schedule FSC Group 66, Part III, Cost-Per-Test Clinical Laboratory Analyzers – Contractors are required to provide a price for each test that can be performed on its equipment. The per test price shall include costs covering (1) 5 year equipment use, (2) all reagents, standards, quality Vendor provided Controls, linearity material, calibration verification material, supplies, consumable/disposable items, parts, accessories and any other item required for the proper operation of the Contractor’s equipment and necessary for the generation and reporting of a test result, (3) all necessary maintenance to keep the equipment in good operating condition (This element includes both preventive maintenance and emergency repairs) and (4) training for Government personnel. Contractors are required to provide delivery, installation and removal of equipment at no additional charge. (5) All necessary items covered and not covered under the cost per reportable that are required to maintain and operate instrument must be listed in bid as well. This includes such things as sample probes, lamps, and other supplies. An estimated usage/cost per year should be included as well.

1.7.3. Business Associate Agreement (BAA)- A business associate is an entity, including an individual, company, or organization that, on behalf of VHA, performs or assists in the performance of functions or activities involving the use or disclosure of PHI, or that provides certain services involving the disclosure of protected health information (PHI). VHA is a covered entity under the HIPAA Privacy Rule (Privacy Rule). HIPAA regulations require VHA to execute HIPAA-compliant BAAs with certain entities that receives, uses, or discloses VHA PHI in order to perform some activity for VHA. These BAAs obligate VHA business associates to provide the same protections and safeguards to PHI that is required of VHA under the Privacy Rule.

1.7.4. Specimen Processing Automation Line – Pre-analytical processing and archival processing equipment that will automate these specimen processing functions, as indicated in the general requirements section.

1.7.5. Specimen Management System - A component of the Processing Automation Line that directs and manages the operation and components of the pre-analytical processing/automation system.

1.7.6. Contractor Middleware Management System - A server installed with software that interfaces the testing instrumentation to the Laboratory Information system and is able to receive, process and send data following CLSI guidelines.

1.7.7. Throughput – The speed that the equipment processes and/or operates reported in units per hour.

1.7.8. TEST MENU: Refer to Attachment A for desired test menu, cutoffs and estimated annual volumes by laboratory.

1.7.8.1. Special testing requirements: See Attachment D4 for references.

1.7.8.1.1. HIV Methodology shall be 4th generation or higher to meet the CDC requirement for HIV testing.

1.7.8.1.2. Rapid testing for cardiac marker High Sensitive Troponin T, 10 minutes or less.

· When it comes to managing acute coronary syndromes, every minute matters. From the time from onset of coronary event until the time the patient receives treatment will affect the outcome of the patient. Time is muscle and any delay is detrimental to patients welfare.

· The following factors also need to be taken into account alongside the assay time.

1. Time taken from the onset of symptoms to the time the patient arrives at the ED.

2. Time taken for the emergency providers to assess patients symptoms.

3. Time taken it takes for blood to be drawn and sent to lab.

4. Time taken for sample to be checked in, centrifuged and loaded on analyzer.

5. Time taken for Lab to report result.

6. Time taken provider interpreting results and implementing treatment plan.

7. Time taken for ED staff performing treatment.

1.7.8.1.3. IDMS traceable Creatinine Reagent is available.

1.7.8.1.4. Rapid testing for intraoperative PTH. 10 minute or less.

· Intraoperative PTH assays that utilize the use of short turn around times on plasma prevents patients undergoing parathyroid surgery from extended time under anesthesia. Typically while a patient is in surgery, a baseline value is obtained. After the adenoma candidate is removed, another sample is obtained 10 minutes later. The surgeon waits on the result to determine if the adenoma removal was successful.

GENERAL REQUIREMENTS:

1.7.8.2. Primary analyzer(s) – Base equipment offered shall be new or instrumentation that is currently in place and shall fully support the scope of operations (minimal requirements). Depending upon the technical functionality and the capabilities of the individual manufacturer’s instrumentation, one analyzer or multiple analyzers may be required to meet the productivity specifications defined herein. Analyzers offered per facility shall provide sufficient capacity and throughput to meet the volume and service demands as defined in Attachment A. In those instances, the additional analyzer(s) shall, likewise, be considered primary instrumentation and shall meet all of the technical specifications of this solicitation. Those additional analyzer(s) offered meeting the definition of a primary analyzer may serve as a back-up analyzer (see definition below) and shall replace the requirement for offering that category of equipment.

1.7.8.3. Back-up Analyzer; equipment required in support of operations for the VA laboratories in the event the primary analyzer(s) becomes non-operational/non-functional. In the instance that the mirror imaged analyzers become unavailable the back-up analyzer will be used. As such, the requirements for consumable supplies, i.e. reagents, quality control material, calibrators, etc., shall be minimal and corollary to the successful operation of the primary instrumentation. Specific tests that require back-up performance are listed in Attachment A. Additional primary analyzers required for the performance of daily workload are not considered back-ups for the purposes of consumables, reagents, etc.

1.7.8.4. Installation Contractor will provide an alternate site for validation of the instrumentation if space is not available for side-by-side validation with existing instrumentation. Contractor will perform, at their cost, new validation studies as defined by the customer when instrumentation is installed in the final workspace.

1.7.9. Operational and Technical Features- The instrumentation offered shall be approved by the Food and Drug Administration (FDA) at the time of proposal submission and have the following:

1.7.9.1. Primary Processing Automation Line Instrumentation. Offering for an Integrated Clinical Laboratory Chemistry/Immunochemistry Instrumentation and Robotics System (Automated track or line) in accordance with the requirements of each respective laboratory, as listed in Attachment D.2, shall have the following listed below. Please include a clear description regarding how samples are transported on the rack.

1.7.9.1.1. Sufficient capacity and throughput to meet the volume and service demands as defined in Attachment A.

1.7.9.1.2. Includes a specimen management system to manage and track sample progress and position.

1.7.9.1.3. Specimen archival through mapping of specimen location; for easy retrieval once moved off-line. (Specimen Management System).

1.7.9.1.4. The ability, based on test requests, to sort and route specimens. (Line/track system/ Specimen Management System)

1.7.9.1.5. The ability to send the primary tube or processed aliquots by means of a tracking system to the proper testing instrumentation to maximize efficiency and to maintain and standardize turnaround times of results. (Line/track system/ Specimen Management System)

1.7.9.1.6. Must be able to integrate with third party systems (for example Diasorin, Sysmex, and Bio-Rad) in order to reduce tech time loading third party instruments.

1.7.9.1.7. Minimal operator intervention to introduce STAT specimens or to change a routine specimen priorities.

1.7.9.1.8. The ability to detect processing errors and provide error notification. (Specimen Management System)

1.7.9.1.9. The ability to separate the serum/plasma from the blood cells through the process of centrifugation. (Centrifuge)

1.7.9.1.10. Ability to detect short samples and clots (Aliquotter)

1.7.9.1.11. The ability to remove caps from blood collection tubes. (Decapper)

1.7.9.1.12. The ability to recap and/or reseal - tubes. (Recapper)

1.7.9.1.13. The ability to remove an aliquot of serum/plasma using disposable pipette tips to prevent contamination and move into another specimen tube or cup for analysis. (Aliquotter)

1.7.9.1.14. The ability to print bar code labels and label daughter (aliquot) tubes to maintain positive specimen identification.

1.7.9.1.15. The ability to connect all primary and back-up testing analyzers offered in accordance with Attachment D.2

1.7.9.1.16. Ensure immediate availability of primary tube after initial testing is completed.

1.7.9.1.17. The ability to auto-archive, store and retrieve specimens. Capacity to be determined by Attachment D.2.

1.7.9.1.18. Barcode reader stations must have the following capabilities:

1.7.9.1.18.1. The accuracy of the barcode reading must have less than a 1.0 % failure rate.

1.7.9.1.18.2. Equipment must be able to support multiple barcode formats (Code 39, Code 128) that may be enabled concurrently.

1.7.9.1.18.3. Equipment must accept, at a minimum, 10 characters in specimen identifier that is alpha, numeric, and/or alphanumeric concurrently.

1.7.9.2. Primary automated sample storage unit. Offering for an sample storage unit that will connect to the Integrated Clinical Laboratory Chemistry/Immunochemistry Instrumentation and Robotics System (Automated track or line).

1.7.9.2.1.1. Sufficient capacity to store VA Portland Healthcare samples for up to one week.

1.7.9.2.1.2. Must include automatic disposal once samples storage period has expired.

1.7.9.2.1.3. Must be temperature controlled to ensure proper sample storage conditions.

1.7.9.2.1.4. Must have the ability to protect light sensitive samples to increase storage stability.

1.7.9.2.1.5. Traceability if samples and data.

1.7.9.3. Testing Instrumentation The testing instrumentation must be an integrated platform with flexible, components that can be upgraded and or reconfigured on site and is approved by the Food and Drug Administration (FDA) at the time of proposal submission and shall have the following:

1.7.9.3.1. The capability of performing analysis on 100% of the tests listed in Attachment A. with no more than 10% repeats of CPRR.

1.7.9.3.2. Sufficient capacity and throughput to meet the volume and service demands as defined in Attachment A.

1.7.9.3.3. An instrument management system (internal to testing instrumentation) that provides/maintains the following:

1.7.9.3.3.1. Ability to monitor instrument performance.

1.7.9.3.3.2. Continuous monitoring of vital functions with immediate operator notification of failure(s) and on-board storage of these records.

1.7.9.3.3.3. Capability to detect and alert operator of out of range quality control results via flagged results on QC printout and visual alerts on display monitor.

1.7.9.3.3.4. Ability to store and retransmit patient records to the VA Laboratory Information system for a minimum 48 hours in case of interface outage.

1.7.9.3.3.5. Capability to record, store and print the following information:

1.7.9.3.3.5.1. Required quality control and instrument maintenance information.

1.7.9.3.3.5.2. Patient demographic information and specimen results.

1.7.9.3.3.6. On board reagent inventory system.

1.7.9.3.4. A bi-directional, bar-coded computer interface compatible with the current VA laboratory information system. The fully operational interface (both hardware and software) shall be immediately available for implementation to the VA computerized hospital information system.

1.7.9.3.4.1. The accuracy of the barcode reading must have less than a 1.0 % failure rate.

1.7.9.3.4.2. Equipment must be able to support multiple barcode formats (Code 39, Code 128) that may be enabled concurrently.

1.7.9.3.4.3. Equipment must accept, at a minimum, characters in specimen identifier that is alpha and/or numeric depending on site that may be enabled concurrently.

1.7.9.4. Bar coding of reagents and the ability to track reagent containers throughout the testing process using bar code technology.

1.7.9.5. Ability to prioritize STAT testing without compromising existing programmed testing.

1.7.9.6. Minimal operator intervention to introduce STAT specimens or to change a routine specimen to a STAT specimen, as well as introduce STAT specimens during a test run without aborting a run. Vendor will outline STAT procedure.

1.7.9.7. On board reagent stability, sufficient to accommodate both high and low volume use. See ATT D.1

1.7.9.8. The ability to detect and alert operator of low reagent levels and the potential of depletion.

1.7.9.9. The ability to load and unload all reagents from the equipment during operation without interrupting testing in progress or have sufficient capacity to enable a complete 24 hours of testing.

1.7.9.10. The ability to support multiple reagent lots of the same reagent on the equipment at the same time with active, valid calibrations.

1.7.9.11. The ability to maintain multiple calibrations per analyte.

1.7.9.12. The capability to calibrate assays during test run without aborting the run.

1.7.9.13. The capabilities to store, print, and retrieve calibration data.

1.7.9.14. For routine (general) chemistry tests, when more than one lot of a given reagent has a valid calibration and quality control material is programmed to run as a control (in the control mode):

1.7.9.14.1.1. Operatory shall be notified if a new lot number is about to be run to ensure that quality control material is performed.

1.7.9.14.1.2. Quality control results will be easily distinguishable i.e., identified by reagent lot number or similar mechanism, on instrument printout or display monitor.

1.7.9.14.1.3. Operator may select to run a test on only a specified lot of reagent even though more than one lot has a valid calibration

1.7.9.15. The ability to continuously load patient specimens.

1.7.9.16. The ability to detect short samples and interfering indices i.e. hemolysis, lipemia, and icterus, on all systems including Chemistry, Immunochemistry and pre-analytics.

1.7.9.17. Clot detection with alert notification.

1.7.9.18. Primary tube sampling from various manufacturers and sizes of evacuated tubes.

1.7.9.19. The instrumentation shall be capable of handling all routine sample collection tubes e.g.: 13x75, 13x100, 16x100. plus, other various sized sample containers i.e., sample cups (0.5, 1.0, and 2.0 ml), carrier tubes and tube inserts.

1.7.9.20. Automatically repeat testing when defined limits are exceeded via auto dilution or sample volume adjustment.

1.7.9.21. The capability to program a test as a repeat with interfacing of results to overlay initial result.

1.7.9.22. Safety features to avoid unnecessary exposure to biohazardous and chemical material. The exposure to and the volume of biohazardous and chemical material generated by the equipment must be minimal and require a minimum amount of handling.

1.7.9.23. For those sites requiring back up analyzers, it is desirable for the backup analyzer to be a mirror image or have the same reagent requirement as the primary analyzer.

1.7.9.23.1. Ability to store and retransmit records (48 hours of maximal instrument throughput) in case of interface outage.

1.7.9.24. Calibration stability adheres to manufacture’s specifications.

1.7.9.25. User defined/Open Channel test capability. In the event that the contractor cannot provide desired assays, the contractor will provide application development support for open channel test implementation.

1.7.10. Contractor Middleware Management System

1.7.10.1. The Contractor shall provide instrumentation and middleware that is compatible with VistA or interfaces directly with Data Innovations Middleware.

1.7.10.2. The Middleware shall be able to communicate via HL7 messages version 1.5 or later.

1.7.10.3. Middleware for clinical chemistry systems should be open for bidirectional interfacing of front end automation, reference laboratories, and laboratory /clinical information systems, third party middleware applications, and laboratory instrumentation, current and future generations, for all other vendors and/or laboratory sections at no additional cost.

1.7.10.4. The Contractor shall provide the server(s) and Data Innovations’ Instrument Manager Middleware software or other middleware that is compatible with VistA, and provide technical support for both the hardware and software for the duration of the contract.

1.7.10.5. All driver development shall be provided by the respective vender, free-of-charge.

1.7.10.6. The middleware should have the ability to interface with regulatory agency applications. i.e. CAP.

1.7.10.7. The Contractor shall assist in the provision of the appropriate software drivers and interfaces for effective use of automated regulatory agency reporting features.

1.7.10.8. The Contractor shall assist in the establishment, testing, deployment, and troubleshooting of the full capacity of the Middleware before implementation date.

1.7.10.9. The Middleware shall contain systems that facilitate the analysis of laboratory pre-analytic, analytic, and post-analytic processes and the generation of summary reports for quality improvement and monitoring efforts.

1.7.10.10. Summary reports shall be interactive, customizable, and accessible on-demand.

1.7.10.11. Reports shall have, at a minimum, the flexibility to display information organized by department, workflow unit, desired time frame, production phase and priority. Software shall have the capability to drill down within the summary reports, identify problematic data and generate corrective action plans.

1.7.10.12. Canned summary reports shall include, at a minimum: Turnaround time, specimen and test volumes, instrument quality control, specimen quality indicators, and % auto-verification, % (and number) repeat tests.

1.7.10.13. The Middleware shall include moving averages system. The Contractor shall establish, test, deploy and troubleshoot the functionality of the moving averages system.

1.7.10.14. The moving average system should have real-time, failure notification capability and an auto verification interrupt function at the analyte, specimen, and patient or instrument level.

1.7.10.15. The Middleware shall include Boolean logic rule writing applications and vendor developed drivers or functionality that enable the use auto-validation/auto-verification in accordance with CAP regulations.

1.7.10.16. The Middleware shall facilitate the development of compound, nested rules with multiple event actions.

1.7.10.17. The middleware rule-writing application should have a visual (point-&-click) graphical user interface consistent with Microsoft Windows application and not require complex programming or coding. It should provide sufficient data elements & granularity so criteria can be defined for patient, specimen and test-level conditions.

1.7.10.18. The Middleware shall be able to query incoming orders and outgoing results and hold either for user review and action.

1.7.10.19. The Middleware shall contain a specimen management system that allows the user to quickly locate any specimen in the system.

1.7.10.20. The Middleware shall have the ability to transmit QC data directly to Bio-Rad Unity Real Time or any other comparable online Quality Control program.

1.7.10.21. The software shall have a system for inventory management that facilitates the tracking of consumables and ordering of supplies, and include pertinent information about the consumables, including, lot numbers, expiration dates, and item numbers. Either in middleware or program that integrates with the middleware.

1.7.10.21.1. Inventory management software must include handheld scanners that work in conjunction with software.

1.7.10.21.2. Must be able to support multi vendor and multiple barcode styles.

1.7.10.21.3. Shall be able to track inventory located in different locations.

1.7.10.22. The software shall have a system capable of monitoring end to end processes. Be able to track samples. Provide dashboards for easy monitoring of instrument issues, sample issues and can be displayed on multiple types of displays. Either in middleware or program that integrates with the middleware,

1.7.10.23. The server(s) must have sufficient memory to store all middleware records for a minimum of 14 days with downloading capability to an external medium for long term storage of patient records and other information.

1.7.10.24. The vendor shall provide an accessible online medium for long term storage for patient records, results and other information with storage capacity to maintain 2 years’ worth of information. Information should be stored in a format that is readable by standard software.

1.7.10.25. Patient status display for technologist review and workflow management for all integrated (linked) testing instrumentation.

1.7.10.26. Ability to retransmit patient records to universal interface system in case of interface outage.

1.7.10.27. Technology to automatically repeat testing based on customer configurable testing criteria (repeat testing)

1.7.10.28. Technology to automatically direct additional specimen testing based on customer-configurable testing criteria (reflex technology).

1.7.10.29. If vendor provides middleware and server, a backup server capable of taking over system functionality in event of primary server failure is provided at no cost.

1.7.10.30. Test Environment or Test Instance of the Middleware in order to be utilized as an isolated environment for testing new systems, configuration changes, instrument interfaces, upgrades, etc. Test System should have the ability to interface with VistA and VistA test Account.

1.7.10.31. It is preferable that the vendor utilize the VA national site-to-site VPN or work with the VA Officer of Cyber and Information Security and Information Security Officers to establish a client-based VPN.

1.7.10.32. Provide a completed copy of the Manufacturer Disclosure Statement for Medical Device Security (MDS2) and VA Form 6550.

1.7.10.33. Contractor shall collaborate with each lab to write/develop protocols to establish customer configurable rules to enhance workflow management and productivity. Vendors will define level and type of support offered.

1.7.10.34. Contractor shall assist customer with optimizing operation and utilization of the data management system to fully integrate desired testing instrumentation enhancing productivity and management of workflow.

1.7.10.35. The Contractor shall provide all hardware, software, lines, adapters, and devices required to connect all Laboratory instruments to the Middleware, including, but not limited to, Lantronix devices or equivalent that are capable of converting DB9 serial to RJ45 Ethernet following RS232 protocols.

1.7.10.36. The Contractor shall provide 24/7 technical support for all hardware and software of the Middleware and its connections.

1.7.10.37. The Contractor shall provide all updates, upgrades, revisions, patches, and fixes at no cost to the Contractee.

1.7.10.38. The Contractor shall provide all necessary information to complete an ISA/MOU, if necessary, to create a VPN for the contractor to directly connect to the Middleware for troubleshooting purposes.

1.7.10.39. The Contractor shall provide all necessary licenses and support for licenses in order for the Laboratory to optimize the utility of the Middleware; i.e. licenses for connections and Thin Client licenses.

1.7.10.40. Remote-access to server for multiple VA users, either with dedicated thin client terminals or via Windows Remote Desktop Connection

1.7.10.41. The Contractor shall provide training for the Middleware prior to implementation, annually thereafter and anytime there is an upgrade where additional training would be beneficial.

1.7.11. Hardware Features- The instrumentation shall have the following:

1.7.11.1. A total equipment footprint that when installed in the laboratory shall not impact the functionality/operations of that laboratory. See Attachment D.3 for current specifications.

1.7.11.2. All monitors/screens will clearly display information in all light conditions.

1.7.11.3. A printer(s) that has the capability of printing a patient report with patient demographic information that includes minimally the patient’s name and accession or unique identifier number (UID).

1.7.11.4. An uninterruptible power supply (UPS) with line conditioner for each instrument provided. (This includes UPS units for sites with automation lines, specimen management systems, data management systems, refrigerated archive storage, etc.,) Each UPS must provide electrical power for a minimum of 15 minutes after electrical power fails and the system must allow for an automatic controlled shutdown to prevent damage to the instrument and data records.

1.7.11.5. If the proposed instrument system requires an independent water system to operate, the vendor will include the water system and all maintenance of the system as part of the CPRR package.

1.7.12. Specific Equipment Requirements- -

1.7.12.1. Single lot of reagent for each test/analyte per shipment with a minimum dating of 90 days.

1.7.12.2. User defined option for patient testing to be disabled if QC failure occurs.

1.7.12.3. The printer should be user defined to print the results real-time or on demand as well as option to print exceptional reports held in the middleware for auto verification purposes.

1.7.12.4. Equipment installation and possible reinstallation should the equipment need to be moved due to construction or laboratory redesign at no additional cost for one (1) location within each site.

1.7.12.5. Equipment will be compatible with facility based limitation such as, but no limited to HVAC for cooling, size to get through doors to the final install location, water supply, drain for wastes. If applicable.

1.7.13. Method Performance/Validation Requirements

Method performance/comparison shall be at the expense of and performed by the Contractor, shall include linearity material and reagents, and be consistent with current CLSI guidelines and related documents, College of American Pathologists (CAP) standards and Federal regulations. All studies performed will be appropriate for the test menu of the respective laboratory to include serum, plasma, urine and body fluids as applicable. All studies must be approved by the local Laboratory Medicine Medical Director and made electronically available. These requirements shall be in effect during installation and any future changes to the test menu and/or method updates.

1.7.13.1.1. Correlation studies for each analyte. A minimum of 20 samples spanning the reportable range shall be run by the present and the proposed method. In systems where multiple sampling modes exist, mode to mode correlation studies must also be performed. Contractor shall analyze results and provide statistical data to support acceptance of the new method for above studies. Statistics shall consist of at least mean, bias, slope, y-intercept, correlation coefficient, ROC analysis.

1.7.13.1.2. Analytical Measurement Range (AMR) Validation shall be performed on proposed instrument(s) for each analyte to validate the reportable range. The material must have values, which are near the low, mid, and high values of the AMR and be of appropriate matrix for the clinical specimens assayed by that method. A minimum 5-point linearity analysis that adheres to the Beer-Lambert Law and spans the entire range shall be performed as a minimum.

1.7.13.1.3. Precision study using normal and abnormal control material. This shall include, at a minimum, within run precision study of 10 normal and 10 abnormal Vendor provided Controls.

1.7.13.1.4. Sensitivity. Sensitivity may be validated concurrently with correlation studies. Mathematical calculations to determine efficiency, sensitivity, false positive rate and false negative rate are applied.

1.7.13.1.5. Specificity Studies. A review of product literature and assay inserts to determine any adverse effects for increased bilirubin, hemolysis, lipemia, or other interfering substances.

1.7.13.1.6. Carryover Studies. Successful carryover studies shall be completed by the contractor on all analyzers during installation, if required. These studies shall be performed using either contractor developed program(s) or program(s) developed by a third party (CAP/CLSI). The programs shall be provided to each laboratory at no charge.

1.7.14. Reference Range- A reference range must be determined for each test following CLSI guidelines. Samples used for the reference range study must be representative of the patient population being tested. Reference range assessment must be performed for each lab. One of the following protocols shall be used:

1.7.14.1. A verification of the manufacturer’s suggested reference range may be performed as long as the suggested range is based on a comparable population of test subjects. The manufacturer shall provide specific information defining how the suggested range was determined. A minimum of 20 reference individuals shall be used to verify the manufacturer’s range. Any apparent outliers should be discarded and new specimens obtained to provide a statistically valid verification.

1.7.14.2. If the suggested manufacturer’s range is not appropriate for the patient population, a reference range shall be established. Establishing a reference must follow CLSI guidelines. This requires a minimum of 120 reference individuals to be used to establish a reference range. The reference interval should be determined using the nonparametric method.

1.7.14.3. If a laboratory is currently using the proposed instrument/reagent system, the “in-use” reference range can be transferred to the “new” system if a method comparison study between the two systems proves to be acceptable. If comparison studies are not acceptable, one of the two above items must be performed.

1.7.15. Reports- The Contractor shall provide to the Contracting Officer and other individuals (designated post-award) a copy of a quarterly report of sales, by ordering facility, within 30 calendar days after the close of each quarter’s business. Reports are to reflect, at a minimum, total net sales amounts before discount, and discount amounts by ordering facility as well as the raw data used to develop these reports. These reports shall be used to monitor the commitment of each facility, reporting the savings realized and shall be shared with each participating facility, personnel associated with acquiring the products, and respective laboratory personnel. Additional invoice charges associated with reagent and/or supply wastage or repair parts included at no charge shall not be accepted. There will be no additional charges for any reports required as part of the IDIQ. These reports will be in an Excel spreadsheet, multiple tabs may be used, to include a VISN summary tab.

1.7.16. Support Features-

1.7.16.1. Commercial marketing. The equipment models being offered shall be in current production as of the date this offer is submitted. For purposes of this solicitation, “current production” shall mean that the clinical laboratory analyzer model is being offered as new equipment. Discontinued models that are only being made available as remanufactured equipment are not acceptable.

1.7.16.2. Start-Up Reagents. The Contractor shall provide all reagents, calibrators, Vendor provided Controls, linearity materials, consumable/disposable items, parts, accessories and any other item included on the list of supplies defined in the Federal Supply Schedule contract and required to validate instruments for operation for performance of acceptance testing. This applies to all equipment as well as additional or replacement equipment placed under the terms and conditions of this IDIQ. The Contractor shall perform/assist, to the satisfaction of the Government, all validation studies including: precision, method comparison with current analyzer, accuracy (recovery), linearity (reportable range), calibration verification, verification of reference interval, and determination of sensitivity and specificity at no cost to the Government. The Contractor shall perform all of the statistical analysis as stated in the Method Performance/Validation section above and provide a hard-copy and electronic copy of data in an organized, clearly comprehensible format.

1.7.16.3. Training. The Contractor shall provide an instrument training program that is coordinated with and timely to the equipment installation, sufficient to the size and scope of the facility’s services and minimally equivalent to the terms and conditions for training defined in the Contractor’s Federal Supply Schedule FSC Group 66, Part III, Cost-Per-Test Clinical Laboratory Analyzers contract. This key operator training for 2 operators shall include training on the operation of the system, data manipulation, and basic trouble shooting and repair for each system. Thereafter, the Contractor shall provide training for minimally one operator per system per facility per year at the discretion of the Government for each model of instrumentation placed. Utilization of the training slots shall be mutually agreed upon between the VA and the Contractor. A training program that involves off-site travel shall include the cost of airfare, room and board for each participant.

1.7.16.3.1. In addition, basic operator training shall be provided by Contractor on-site for all operators on all shifts, as applicable.

1.7.16.4. Equipment Preventative Maintenance/Repair Service. The Contractor shall be able to provide, at no cost to the Contractee, emergency equipment repair and preventative maintenance on all primary and back-up instrumentation, primary processing automation line instrumentation and any incremental support/ancillary equipment, e.g. water system, printers, UPS, etc. offered according to the following terms:

1.7.16.4.1. Service Requirements

1.7.16.4.1.1. A technical assistance center shall be available by telephone 24 hours per day, 7 days per week with a maximum call back response time of 1 hour

1.7.16.4.1.2. Location and hours of operations are as follows:

Portland - 648 Portland Campus, 3710 SW U.S. Veterans Hospital Road, Portland, OR 97239 24hrs, 7 days a week

1.7.16.4.1.3. Equipment repair service shall be provided for each facility during operational hours listed in 2.2.16.4.1.2. Most repairs will take place during normal business hours, certain circumstances may dictate the need for repair service to be conducted outside routine business hours. All such arrangements shall be coordinated between the Contractor and VA laboratory personnel. Equipment repair response time shall be no more than 24 hours.

1.7.16.4.1.4. Remote Access diagnostic trouble shooting capabilities available with a national ISO Internet Security agreement.

1.7.16.4.1.5. Preventative maintenance will be performed as frequently as published in manufacturer’s operator’s manual and within 2 weeks of the scheduled due date.

1.7.16.4.1.6. A malfunction incident report shall be furnished to the Laboratory upon completion of each repair call, within 24 hours of the repair. The report shall include, as a minimum, the following:

1.7.16.4.1.6.1. date and time notified

1.7.16.4.1.6.2. date and time of arrival

1.7.16.4.1.6.3. serial number, type and model number of equipment

1.7.16.4.1.6.4. time spent for repair, and

1.7.16.4.1.6.5. proof of repair that includes documentation of a sample run of quality control verifying acceptable performance.

1.7.16.4.2. Each notification for an emergency repair service call shall be treated as a separate and new service call.

1.7.16.4.3. Uptime Guarantee/Performance Penalty: The vendor agrees that all equipment provided shall be operable no less than 98% of operational time. Each instrument at each site shall be computed separately.

2.2.17.4.3.1 Operational time is defined in section 2.2.17.4.1.2. which includes hours and days per location.

2.2.17.4.3.2 Downtime is defined as the inability to produce clinically acceptable results for any given parameters and will be computed from the time of initial notification until the instrument is operational and produces clinically acceptable results.

2.2.17.4.3.3 Scheduled maintenance is excluded from downtime.

2.2.17.4.3.4 Vendor will provide a Downtime Summary report of instrumentation prior to the award of contract. Please provide a monthly report of how often and how long your Instruments are down historically. The report should identify which component (including preanalytics) and include:

2.2.17.4.3.4.1 Average number of downtimes monthly

2.2.17.4.3.4.2 Average hours of downtime monthly

2.2.17.4.3.4.3 Average number of downtime calls from customers per year.

2.2.17…